Francisco J. Esteva: How the MammaPrint test could identify patients who benefit from varying durations of EET
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:
“The MammaPrint test, a 70-gene expression assay, is being evaluated for its ability to predict late recurrence risk and the benefit of extended endocrine therapy, EET in early-stage breast cancer patients.
In the IDEAL trial, which studied the duration of extended adjuvant letrozole therapy, Laura van ‘t Veer et al. performed a secondary analysis to see how the MammaPrint test could identify patients who benefit from varying durations of EET.
Among 515 postmenopausal women with hormone receptor-positive early-stage breast cancer, those with low-risk tumors showed significant benefit when treated with 5 years of EET, compared to 2.5 years, in reducing distant recurrence.
For high-risk or ultralow risk tumors, no significant difference was noted between 5 and 2.5 years of EET in reducing distant recurrence.
Takeaway: The MammaPrint assay may guide decisions on the duration of adjuvant endocrine therapy, particularly for patients with low-risk tumors.”
Authors: Laura J. van ’t Veer, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Cornelis J. H. Van de Velde, Miranda Kleijn, Christa Dreezen, Andrea R. Menicucci, William Audeh, Gerrit-Jan Liefers,
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023